Physician profile
Sumana Moole
NPI 1104855949
$681.57
in general payments reported to CMS, 2019-2025
14 companies · $407 in 2025
The $407 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.02 · 2024: $231 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $139.64 | 2024-2025 | Dupixent |
| Pfizer INC. | $112.64 | 2024-2025 | |
| Abbvie INC. | $80.93 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.34 | 2024-2025 | Eohilia, Entyvio |
| Qol Medical, LLC | $57.03 | 2025 | Sucraid |
| Olympus America INC. | $34.35 | 2024 | Evis Exera III Colonovideoscope |
| Genzyme Corporation | $32.20 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.00 | 2019 | |
| Janssen Biotech, INC. | $29.90 | 2019-2024 | Tremfya |
| Janssen Pharmaceuticals, INC | $22.66 | 2025 | Spravato |
| Madrigal Pharmaceuticals | $22.47 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $22.24 | 2025 | Voquezna |
| Phadia US INC. | $19.84 | 2024 | Immunocap |
| Ardelyx, INC. | $18.33 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumana Moole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.